C57BL/6JCya-Fgfr4em1flox/Cya
Common Name
Fgfr4-flox
Product ID
S-CKO-02417
Backgroud
C57BL/6JCya
Strain ID
CKOCMP-14186-Fgfr4-B6J-VA
Status
When using this mouse strain in a publication, please cite “Fgfr4-flox Mouse (Catalog S-CKO-02417) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
Basic Information
Strain Name
Fgfr4-flox
Strain ID
CKOCMP-14186-Fgfr4-B6J-VA
Gene Name
Product ID
S-CKO-02417
Gene Alias
Fgfr-4
Background
C57BL/6JCya
NCBI ID
Modification
Conditional knockout
Chromosome
Chr 13 (Mouse)
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Transcript ID
ENSMUST00000005452
NCBI Transcript ID
NM_008011
Target Region
Exon 6~11
Size of Effective Region
~4.2 kb
Overview of Gene Research
Fgfr4, short for fibroblast growth factor receptor 4, is a receptor tyrosine kinase. It is involved in multiple cellular processes such as cell survival, proliferation, migration, and angiogenesis through its associated fibroblast growth factor (FGF) signaling pathway [4]. Dysregulation of Fgfr4 signaling has been implicated in oncogenesis, tumor progression, and resistance to anti-tumor therapy in various cancers, highlighting its biological importance. Genetic models are valuable for studying its functions.
In hepatocellular carcinoma (HCC), Fgfr4, along with FGF19, jointly upregulates ETV4 expression via the ERK1/2 pathway, and ETV4 in turn upregulates Fgfr4 expression, creating a positive feedback loop that facilitates HCC metastasis by upregulating PD-L1 and CCL2 [1]. In HER2-positive breast cancer, FGFR4 inhibition enhances susceptibility to anti-HER2 therapy. m6A-hypomethylation regulated Fgfr4 phosphorylates GSK-3β and activates β-catenin/TCF4 signaling to drive anti-HER2 resistance, and its suppression triggers ferroptosis [2]. In luminal breast cancer, Fgfr4 regulates tumor subtype differentiation and metastatic disease, and its inhibition can cause molecular switching [3]. In rhabdomyosarcoma, FGFR4 is highly expressed in tumors and lowly in healthy tissues, and CAR T-cell therapy targeting FGFR4 shows promise in preclinical models [5]. In colorectal cancer, ELF4 transactivates Fgfr4 to promote metastasis, and the combination of a FGFR4 inhibitor and an SRC inhibitor can suppress this metastasis [6]. In HCC, KDM6A promotes HCC progression by upregulating Fgfr4 expression and influences the efficacy of lenvatinib therapy [7].
In conclusion, Fgfr4 plays a crucial role in cancer development and progression, especially in breast, liver, and colorectal cancers. The study of Fgfr4 using gene knockout or conditional knockout mouse models (although not specifically detailed in these abstracts but generally relevant in the context) has revealed its functions in tumor metastasis, subtype differentiation, and treatment resistance, providing potential therapeutic targets for these diseases.
References：
1. Xie, Meng, Lin, Zhuoying, Ji, Xiaoyu, Huang, Wenjie, Xia, Limin. 2023. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. In Journal of hepatology, 79, 109-125. doi:10.1016/j.jhep.2023.02.036. https://pubmed.ncbi.nlm.nih.gov/36907560/
2. Zou, Yutian, Zheng, Shaoquan, Xie, Xinhua, Tang, Hailin, Xie, Xiaoming. 2022. N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. In Nature communications, 13, 2672. doi:10.1038/s41467-022-30217-7. https://pubmed.ncbi.nlm.nih.gov/35562334/
3. Garcia-Recio, Susana, Thennavan, Aatish, East, Michael P, Prat, Aleix, Perou, Charles M. . FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. In The Journal of clinical investigation, 130, 4871-4887. doi:10.1172/JCI130323. https://pubmed.ncbi.nlm.nih.gov/32573490/
4. Levine, Kevin M, Ding, Kai, Chen, Lyuqin, Oesterreich, Steffi. 2020. FGFR4: A promising therapeutic target for breast cancer and other solid tumors. In Pharmacology & therapeutics, 214, 107590. doi:10.1016/j.pharmthera.2020.107590. https://pubmed.ncbi.nlm.nih.gov/32492514/
5. Tian, Meijie, Wei, Jun S, Shivaprasad, Nityashree, Cheuk, Adam T, Khan, Javed. 2023. Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma. In Cell reports. Medicine, 4, 101212. doi:10.1016/j.xcrm.2023.101212. https://pubmed.ncbi.nlm.nih.gov/37774704/
6. Chen, Xilang, Chen, Jie, Feng, Weibo, Wu, Kaichun, Xia, Limin. 2023. FGF19-mediated ELF4 overexpression promotes colorectal cancer metastasis through transactivating FGFR4 and SRC. In Theranostics, 13, 1401-1418. doi:10.7150/thno.82269. https://pubmed.ncbi.nlm.nih.gov/36923538/
7. Guo, Wenyun, Li, Songling, Qian, Yifei, Gao, Wei-Qiang, Liu, Yanfeng. . KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression. In Clinical and translational medicine, 13, e1452. doi:10.1002/ctm2.1452. https://pubmed.ncbi.nlm.nih.gov/37846441/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
